A. Mark Schobel's most recent trade in Aquestive Therapeutics Inc was a trade of 50,000 Common Stock done at an average price of $6 . Disclosure was reported to the exchange on March 15, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 15 Mar 2024 | 50,000 | 984,476 (2%) | 0% | 6 | 300,000 | Common Stock | |
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 09 Mar 2024 | 9,645 | 980,726 (2%) | 0% | 4.9 | 47,068 | Common Stock | |
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | Sale of securities on an exchange or to another person at price $ 5.19 per share. | 08 Mar 2024 | 25,000 | 1,040,371 (3%) | 0% | 5.2 | 129,685 | Common Stock |
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.88 per share. | 08 Mar 2024 | 5,895 | 1,034,476 (3%) | 0% | 4.9 | 28,768 | Common Stock |
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 07 Mar 2024 | 82,500 | 1,065,371 (3%) | 0% | 0 | Common Stock | ||
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 07 Mar 2024 | 41,250 | 41,250 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 09 Aug 2023 | 50,000 | 50,000 | - | - | Performance Stock Units | ||
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 05 May 2023 | 50,000 | 50,000 | - | - | Performance Stock Units | ||
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 09 Mar 2023 | 100,000 | 982,871 (2%) | 0% | 0 | Common Stock | ||
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 04 Nov 2022 | 40,000 | 40,000 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 08 Jun 2022 | 45,871 | 45,871 | - | - | Warrant (Right to Buy) | ||
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 08 Jun 2022 | 45,871 | 882,871 (2%) | 0% | 1.0 | 44,036 | Common Stock | |
| Aquestive Therapeutics Inc | A. Mark Schobel | Chief Innovation/Tech Officer | 10 Mar 2022 | 75,000 | 75,000 | - | - | Non-Qualified Stock Option (right to buy) |